Hypersensitivity Reactions to Biological Drugs

Riedl, 2003, Adverse drug reactions: types and treatment options, Am Fam Physician, 68, 1781 deShazo, 1997, Allergic reactions to drugs and biologic agents, JAMA, 278, 1895, 10.1001/jama.1997.03550220101014 Weiss, 2001, Miscellaneous toxicities, 2964 Shepherd, 2003, Hypersensitivity reactions to drugs: evaluation and management, Mount Sinai J Med, 70, 113 Gobel, 2005, Chemotherapy-induced hypersensitivity reactions, Oncol Nurs Forum, 32, 1027, 10.1188/05.ONF.1027-1035 Ream, 2001, Hypersensitivity reactions, 271 Thomas, 2004 Winkler, 1999, Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8), Blood, 94, 2217, 10.1182/blood.V94.7.2217.419k02_2217_2224 Ditto, 2002, Drug allergy, part A: Introduction, epidemiology, classification of adverse reactions, immunochemical basis, risk factors, evaluation of patients with suspected drug allergy, patient management considerations, 295 Barranco, 1998, General and epidemiological aspects of allergic drug reactions, Clin Exp Allergy, 28, 61 Bayard, 1992, Drug hypersensitivity reactions and human immunodeficiency virus disease, J Acquir Immune Defic Syndr, 5, 1237, 10.1097/00126334-199212000-00008 Descamps, 2001, Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms, Arch Dermatol, 137, 301 Lang, 1991, Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma, Ann Intern Med, 115, 270, 10.7326/0003-4819-115-4-270 Petri, 1992, Antibiotic allergy in systemic lupus erythematous: a case-control study, J Rheumatol, 19, 265 Adkinson, 1984, Risk factors for drug allergy, J Allergy Clin Immunol, 74, 567, 10.1016/0091-6749(84)90108-8 Cheng, 2000, Recent advances in immunotherapy and monoclonal antibody treatment of cancer, Semin Oncol Nurs, 16, 2, 10.1053/sonu.2000.19775 Rieger, 2001, Monoclonal antibodies: Applications in solid tumors and other diseases, 317 2003 Zanotti, 2001, Prevention and management of antineoplastic-induced hypersensitivity reactions, Drug Safety, 24, 767, 10.2165/00002018-200124100-00005 Drain, 2001, Preventing and managing drug-induced anaphylaxis, Drug Safety, 24, 843, 10.2165/00002018-200124110-00005 Lieberman, 2005, The diagnosis and management of anaphylaxis: an updated practice parameter, J Allergy Clin Immunol, 115, S483, 10.1016/j.jaci.2005.01.010 Labovich, 1999, Acute hypersensitivity reactions to chemotherapy, Semin Oncol Nurs, 15, 222, 10.1016/S0749-2081(99)80010-2 Yeung, 2000, Oncologic emergencies, 2659 Busam, 2001, Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225, Br J Dermatol, 144, 1169, 10.1046/j.1365-2133.2001.04226.x Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, 351, 337, 10.1056/NEJMoa033025 Monti, 2003, Complications of therapy and a diagnostic dilemma case, J Clin Oncol, 21, 4651, 10.1200/JCO.2003.04.169 Saltz, 2004, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor, J Clin Oncol, 22, 1201, 10.1200/JCO.2004.10.182 Raben, 2002, ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination as a new therapeutic strategy in non-small cell lung cancer, Semin Oncol, 29, 37, 10.1053/sonc.2002.31521 van Doorn, 2002, Follicular and epidermal alterations in patients treated with ZD1839 (Iressa) an inhibitor of the epidermal growth factor receptor, Br J Dermatol, 147, 598, 10.1046/j.1365-2133.2002.04864.x Perez-Soler, 2003, Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?, Oncology, 17, 23 Susman, 2004, Rash correlates with tumour response after cetuximab, Lancet Oncol, 5, 647, 10.1016/S1470-2045(04)01627-4 2005 2005 2003 Foss, 2001, Biological correlates of acute hypersensitivity events with DAB (389) IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication, Clin Lymphoma, 1, 298, 10.3816/CLM.2001.n.005 Olsen, 2001, Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma, J Clin Oncol, 19, 376, 10.1200/JCO.2001.19.2.376 Osterborg, 1997, Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukaemia, J Clin Oncol, 15, 1567, 10.1200/JCO.1997.15.4.1567 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2334, 10.1056/NEJMoa032691 2006 Herbst, 2002, Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-225 in the treatment of lung and head and neck cancers, Semin Oncol, 29, 27, 10.1053/sonc.2002.31525 Sievers, 2001, Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse, J Clin Oncol, 19, 3244, 10.1200/JCO.2001.19.13.3244 2006 Wiseman, 1999, Radioimmunotherapy of relapsed non-Hodgkin’s lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody, Clin Cancer Res, 5, 3281s DeNardo, 2002, Treatment of non-Hodgkin’s lymphoma (NHL) with radiolabeled antibodies (mAbs), Semin Nucl Med, 35, 202, 10.1053/j.semnuclmed.2005.02.006 2007 2002 Maloney, 2001, Rituximab for the treatment of patients with B-cell non-Hodgkin’s lymphoma, 204 Plosker, 2003, Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, Drugs, 63, 803, 10.2165/00003495-200363080-00005 Kaminski, 2001, Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas, J Clin Oncol, 19, 3918, 10.1200/JCO.2001.19.19.3918 2006 2006 Runge, 1992, Histamine antagonists in the treatment of acute allergic reactions, Ann Emerg Med, 21, 237, 10.1016/S0196-0644(05)80881-9 2005, Joint Task Force on Practice Parameters, J Allerg Clin Immunol, 3, S438 Brown, 1998, Therapeutic controversies in the management of acute anaphylaxis, J Acc Emerg Med, 15, 89, 10.1136/emj.15.2.89